Navigation Links
Barnes-Jewish Hospital First in Area to Treat Peripheral Artery Disease with New Drug-Eluting Stent
Date:9/23/2013

St. Louis (PRWEB) September 24, 2013

Although drug-coated stents have been commonly used in coronary procedures, the technology is new to the treatment of peripheral artery disease (PAD). Patrick Geraghty, MD, FACS, Washington University vascular surgeon at Barnes-Jewish Hospital, is the first in the regional area to implant a new drug-eluting stent to treat symptomatic blockages of leg arteries.

A new era for minimally invasive treatment of leg artery blockages:

One in every 20 Americans over the age of 50 has been diagnosed with PAD. The new drug-eluting stent delivers a significant advance in their treatment. In the past decade, physicians at the Washington University and Barnes-Jewish Heart & Vascular Center have used drug-eluting stents in the small arteries of the heart with excellent results.

“At last, we can use the same technology to dramatically improve the outcomes of stent placement in the thigh artery (also known as the superficial femoral artery or SFA), the most common location of blockages due to PAD,” says Dr. Geraghty.

The stents that were previously used to treat these blockages suffered from a significant failure rate during the first few years after implantation. This failure was caused by reactive scarring that would obstruct blood flow in the stented artery. This new stent slowly releases a drug, paclitaxel, into the surrounding arterial wall, greatly reducing the scarring process.

“The U.S. Food and Drug Administration (FDA) performs rigorous testing before these new devices are granted approval for patient use,” says Dr. Geraghty. “As one part of the FDA approval testing, the drug-eluting stent was compared to a stent that was constructed in an identical fashion, except that it did not release paclitaxel. Not only did the drug-eluting stent diminish the rate of stent failure, but that beneficial result was sustained over three years of follow-up. In fact, three years after the initial procedure, stent failure was reduced by more than 50 percent in patients who received the drug-eluting stent. That’s a game-changer.”

Walking without pain:

“The sustained improvement in stent patency makes this ideal for the treatment of claudication,” says Dr. Geraghty. “Claudication occurs when thigh artery blockages cause the leg muscles to rapidly tire and become sore with walking. Our first line of therapy is medical management and structured exercise. If patients do not respond to those simple measures, use of the drug-eluting stent will allow us to restore their ability to walk, while reducing their risk for needing repeat interventions.”

The device is implanted in the artery using a slender catheter that is introduced at the groin area. This outpatient procedure does not require a surgical incision or general anesthetic.

Preventing amputation:

In critical limb ischemia (CLI) patients, leg blood flow is reduced to the point that patients experience constant foot pain, ischemic sores and are at high risk for amputation.

“We’re excited about the use of this new technology as part of our treatment for CLI patients. These are patients with more severe artery blockages,” says Dr. Geraghty. “We specialize in the complex care that these patients require, and I’ve already treated CLI patients successfully with this new device. It’s a valuable tool in our efforts to reduce the number of amputations in the St. Louis region."

Barnes-Jewish Hospital is the only hospital in the region currently offering this device for the treatment of PAD.

The Zilver PTX stent, made by Cook Medical, was approved by the Food and Drug Administration Nov. 15, 2012.

For more information about the treatment of peripheral artery disease, call 855-45-HEART.

###

Barnes-Jewish Hospital is a 1,315 bed teaching hospital affiliated with Washington University School of Medicine in St. Louis, Mo. The hospital has a 1,763 member medical staff, with many recognized as "Best Doctors in America." Barnes-Jewish is a member of BJC HealthCare, which provides a full range of health care services through its 13 hospitals and more than 100 health care sites in Missouri and Illinois. Barnes-Jewish Hospital is also consistently ranked as one of America’s “Best Hospitals” by U.S. News & World Report.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11147458.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Washington University and Barnes-Jewish Hospital Lung Transplant Program Celebrates 25 Years
2. New Release Announced: Updated Hospital Information in the AHA Guide®
3. VHA SupplyNetworks® Leverage Scale to Generate Greater Cost Savings for Hospitals from West Virginia to New York
4. The American Hospital Association Exclusively Endorses Equipment Financing from First American Healthcare Finance
5. St. Vincent Hospital and Lakeview Health Join Forces Against Rising Jacksonville Addiction
6. Florida Hospital Carrollwood Pink Army Marches into Tampa Troops Enlisted to Join the Fight Against Breast Cancer
7. Hospital Asset Management Market to Post 20 Percent CAGR Through 2017, According to M&M Report Published at MarketPublishers.com
8. Loma Linda University Children’s Hospital Patient Visits KFROG Radiothon, First Public Outing in 10 Months
9. Imprivata is the Most Widely Selected Single Sign-On Solution by U.S. Hospitals Using McKesson Paragon or Horizon According to HIMSS Analytics
10. The American Hospital Association Awards Exclusive Endorsement to Walgreens WellTransitions® Program for Medication Adherence
11. Pregnant women with high/low BMI are at higher risk of complications and hospital admissions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: